Lupin Pharmaceuticals Inc. and a group of end payors won preliminary approval of a $1 million settlement to end their portion of multidistrict litigation accusing the drugmaker and two other pharmaceutical companies of colluding to keep generic versions of the birth control drug Loestrin off the market.
U.S. District Judge William E. Smith's initial approval of the $1 million settlement on Wednesday came more than three months after a host of end payors, including the city of Providence, Rhode Island, health insurance companies and employee welfare benefit programs, asked that the court greenlight it.
The judge has also certified the end payors settlement class and named Motley Rice LLC, Miller Law LLC, Hilliard & Shadowen LLP and Cohen Milstein Sellers & Toll PLLC as co-lead class counsel. Motley Rice LLC will serve as liaison counsel, and the judge has also set a Jan. 21, 2019, final fairness hearing, according to the order.
The complete article can be accessed here.